ACTIVE SESSION TAPE Biotechnology $45M Cap Quant: HOLD

Why Is Radiopharm Theranostics Limited (RADX) Stock Down Today?

Updated Nov 22, 2026 5:31 AM ET ยท Prev Close $0.67

Pro Workspace
Last Session Price
$0.63 -6.33%
-$0.04 vs $0.67 prior close
Intraday Range
$0.63 โ€“ $0.72
Open $0.67
Relative Volume
0.28x Avg
12,467 sh
52-Week Range
$0.63 โ€“ $16.25
Benchmark Alpha
-2.69% vs SPY
-0.66% vs QQQ
20-Session Trend -36.7%

Session Regime & Catalyst Assessment

68% Signal Conviction
TECHNICAL 68% Driver Weight

Radiopharm Theranostics Limited Pulling Back 6.33% on 0.28x Relative Volume

Radiopharm Theranostics Limited (RADX) is pulling back 6.33% (-$0.04) to $0.63 on 0.28x average session volume. Relative to benchmarks, RADX is lagging the S&P 500 by -2.69%. 14-day RSI stands at 26.9, keeping momentum in a oversold regime.

NEWS 70% Weight
Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting

Concordance between 18F-RAD101 Pet and contrast-enhanced MRI 93.5 patient-level agreement preliminary sensitivity of 85.7 against the reference standard Favourable safety profile with no serious treatment-emergent advers

TECHNICAL 68% Weight
Moving Average Structure: Bearish Alignment

Price ($0.63) trades relative to 20-day SMA ($0.86) and 50-day SMA ($1.15).

Volume Confirmation
LOW VOLUME (0.28x) Consolidation
Sub-average participation โ€” monitor RVOL expansion above 1.2x.
Composite Catalyst Confidence 68%
Cross-checked across volume tape, benchmark alpha, options flow, and news.

Market & Sector Relative Strength

RADX lagging the S&P 500 by -2.69%
RADX Session
-6.33%
$0.63
S&P 500 (SPY)
-3.64%
$689.81
Nasdaq 100 (QQQ)
-5.67%
$608.45
Healthcare (XLV)
-0.12%
$177.24
Alpha vs SPY: -2.69% Alpha vs QQQ: -0.66% Alpha vs XLV: -6.21%

Options Flow & Execution Desk

Recent RADX Catalyst Headlines

Verified Wire
Radiopharm Theranostics Reports Business Update

Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration Reported positive Phase 1 im

Yahoo Finance ยท Nov 02, 2026

1โ€“3 Day Expected Range & Key Level

48% Follow-Through
Lower Bound
$0.60
Short-term support band
Upper Bound
$0.66
Short-term resistance band
Key Inflection Level
$0.63 (session support)

Monitor volume expansion above 1.5x RVOL around $0.63 (session support) for directional breakout confirmation.

Technical Regime (RADX)

BEARISH MA TREND
RSI (14)
26.9
Oversold
20-Day SMA
$0.86
Below 20d
50-Day SMA
$1.15
Below 50d
MACD Signal
Bearish
MACD -0.15
ADX (14)
25.1
Strong trend
10d Momentum
-0.33
Soft 10-day momentum

About Radiopharm Theranostics Limited

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Sector
Healthcare
Market Cap
$45M

Get Instant RADX Catalyst Alerts

Receive an email alert when RADX triggers an unusual volume breakout, options sweep, or rating shift.

RADX Session & Catalyst FAQ

Why is RADX stock down today?

Radiopharm Theranostics Limited (RADX) is pulling back 6.33% (-$0.04) to $0.63 on 0.28x average session volume. Relative to benchmarks, RADX is lagging the S&P 500 by -2.69%. 14-day RSI stands at 26.9, keeping momentum in a oversold regime.

Is RADX stock a buy or sell right now?

Today's session carries a 68% catalyst conviction score on 0.28x relative volume (low participation). Our multi-factor model currently rates RADX as HOLD. Review full valuation, quality, and timing signals on the RADX Buy or Sell Decision Brief โ†’

What is RADX's intrinsic value and expected trading range?

At $0.63, RADX's modeled 1-to-3 session range is $0.60 โ€“ $0.66, with a key inflection level at $0.63 (session support). Compare current price against multi-year cash flow projections in the RADX Intrinsic Value & DCF Model โ†’ and Market Cycle Phase Tracker โ†’

What do RSI and moving averages signal for RADX?

RSI at 26.9 indicates oversold conditions โ€” watch for mean-reversion support. RADX trades at $0.63 relative to its 20-day SMA ($0.86) and 50-day SMA ($1.15), reflecting a bearish moving-average structure.

Tradestie Flagship Research & Market Hubs